GlassScriptPhysician profile
Vicky M Moe
NPI 1265662431
$1,082.83
in general payments reported to CMS, 2019-2025
16 companies · $906 in 2025
The $906 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.02 · 2022: $49.37 · 2024: $113 · 2025: $906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,018.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,018.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $188.64 | 2025 | Otezla, Repatha, Krystexxa |
| Astellas Pharma US INC | $135.06 | 2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $130.75 | 2024-2025 | Breztri |
| Pfizer INC. | $126.70 | 2024-2025 | |
| Novo Nordisk INC | $112.01 | 2024-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $106.71 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $66.56 | 2025 | |
| Glaxosmithkline, LLC. | $63.76 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Corcept Therapeutics | $28.16 | 2025 | Korlym |
| Sumitomo Pharma America, INC. | $24.70 | 2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $20.37 | 2025 | Rotateq, Vaxneuvance, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $18.07 | 2025 | |
| Idorsia Pharmaceuticals US INC | $15.97 | 2024 | Quviviq |
| Actelion Pharmaceuticals US, INC. | $15.41 | 2025 | Opsumit |
| Abbott Laboratories | $15.02 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vicky Moe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.